Pamela Esposito - Replimune Chief Business Officer
| REPL Stock | USD 13.26 1.67 11.19% |
Executive
Dr. Pamela Esposito, Ph.D., is Chief Business Officer of the Company. Previously, she was Chief Business Officer at Ra Pharmaceuticals, Inc., or Ra, from 2013 to 2015. As a member of Ra senior management team, Dr. Esposito played a leadership role in strategy, helping Ra transform from a discovery platform to a clinicalstage company. Prior to Ra, from 2010 to 2011, she was Vice President of Business Development at BioVex since 2015.
| Age | 50 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 500 Unicorn Park Drive, Woburn, MA, United States, 01801 |
| Phone | 781 222 9600 |
| Web | https://www.replimune.com |
Pamela Esposito Latest Insider Activity
Tracking and analyzing the buying and selling activities of Pamela Esposito against Replimune stock is an integral part of due diligence when investing in Replimune. Pamela Esposito insider activity provides valuable insight into whether Replimune is net buyers or sellers over its current business cycle. Note, Replimune insiders must abide by specific rules, including filing SEC forms every time they buy or sell Replimune'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Pamela Esposito over three months ago Disposition of 5000 shares by Pamela Esposito of Replimune at 15.5 subject to Rule 16b-3 | ||
Pamela Esposito over six months ago Disposition of 15000 shares by Pamela Esposito of Replimune subject to Rule 16b-3 |
Replimune Management Efficiency
The company has return on total asset (ROA) of (0.2707) % which means that it has lost $0.2707 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5032) %, meaning that it created substantial loss on money invested by shareholders. Replimune's management efficiency ratios could be used to measure how well Replimune manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.46. The value of Return On Capital Employed is expected to slide to -0.55. At this time, Replimune's Net Tangible Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.10 this year, although the value of Total Assets will most likely fall to about 359.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ellen Cavaleri | Lyra Therapeutics | N/A | |
| David Liu | Protagonist Therapeutics | 74 | |
| MS MBA | Kura Oncology | 50 | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Carena Spivey | Protagonist Therapeutics | N/A | |
| Dilip Kodira | PureTech Health PLC | N/A | |
| Matthew Moore | Ventyx Biosciences | 51 | |
| Anita JD | PureTech Health PLC | N/A | |
| David MD | Mineralys Therapeutics, Common | 69 | |
| Cheryl Murphy | PureTech Health PLC | N/A | |
| Douglas Kling | NewAmsterdam Pharma | 51 | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| Jim Jacobson | NewAmsterdam Pharma | N/A | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| Mayur Somaiya | NewAmsterdam Pharma | 50 | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| John Bishop | Lyra Therapeutics | 62 | |
| Richard MD | Lyra Therapeutics | 61 | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
| Caryn Peterson | Gossamer Bio | 65 | |
| BSc MD | Aerovate Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 |
Replimune Group Leadership Team
Elected by the shareholders, the Replimune's board of directors comprises two types of representatives: Replimune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Replimune. The board's role is to monitor Replimune's management team and ensure that shareholders' interests are well served. Replimune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Replimune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Coffin, President CEO, Director | ||
| Sushil Patel, Chief Officer | ||
| Colin Love, Chief Officer | ||
| Christopher Sarchi, Chief Officer | ||
| Tanya MS, Chief Officer | ||
| Philip FSA, Executive Chairman | ||
| Pamela Esposito, Chief Business Officer | ||
| Emily Hill, Chief Officer | ||
| Paul Bullock, Chief Head | ||
| Andrew Schwendenman, Chief Treasurer | ||
| MBA MD, Chief Officer | ||
| Jean Franchi, CFO, Officer |
Replimune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Replimune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 665.54 M | ||||
| Shares Outstanding | 68.42 M | ||||
| Shares Owned By Insiders | 4.71 % | ||||
| Shares Owned By Institutions | 95.29 % | ||||
| Number Of Shares Shorted | 7.05 M | ||||
| Price To Book | 2.68 X | ||||
| EBITDA | (230.2 M) | ||||
| Net Income | (215.79 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.